# Uterine Cervix repeated Magnetic Resonance Imaging for adaptive treatment planning of cervical cancer radiotherapy. A single-center study

Published: 12-11-2015 Last updated: 19-04-2024

To develop an MRI-guided adaptive radiotherapy workflow for patients with locally advanced cervical cancer, aimed at achieving more precise target coverage and better critical organ sparing.

Ethical review Approved WMO

**Status** Recruitment stopped

Health condition type Reproductive neoplasms female malignant and unspecified

**Study type** Observational invasive

# **Summary**

#### ID

NL-OMON42497

#### **Source**

ToetsingOnline

#### **Brief title**

CeReMony

#### **Condition**

Reproductive neoplasms female malignant and unspecified

#### **Synonym**

Cervical cancer

#### Research involving

Human

# **Sponsors and support**

**Primary sponsor:** Universitair Medisch Centrum Utrecht

1 - Uterine Cervix repeated Magnetic Resonance Imaging for adaptive treatment planni ... 11-05-2025

Source(s) of monetary or material Support: Ministerie van OC&W

#### Intervention

**Keyword:** adaptive, cervix, MRI, radiotherapy

#### **Outcome measures**

#### **Primary outcome**

We will develop a new workflow for MRI-guided adaptive radiotherapy, assessing the accuracy of semi-automatic delineation of target volume and critical organs. Treatment remains according to standard clinical practice, but we will (digitally) simulate our new workflow using the acquired MRI scans.

#### **Secondary outcome**

NA

# **Study description**

### **Background summary**

Standard therapy for locally advanced cervical cancer (International Federation of Gynecology and Obstetrics (FIGO) stages IB2, IIA2, IIB, IIIA, IIIB, or IVA) [1] is chemoradiotherapy (CRT). Common side effects from this treatment are cystitis, enteritis, proctitis, bone marrow suppression and vaginal stenosis [2-6]. These side effects influence quality of life, and also limit further extension of the radiation fields, and/or the introduction of adjuvant chemotherapy, for high-risk patients.

Adaptive radiotherapy, in which treatment margins are safely reduced using daily imaging, holds great promise for minimization of side effects from radiotherapy. In this study, we want to simulate and develop a new workflow for MRI-guided adaptive radiotherapy. We propose to simulate daily imaging by acquiring three additional MRI scans during regular clinical treatment for locally advanced cervical cancer.

#### Study objective

To develop an MRI-guided adaptive radiotherapy workflow for patients with locally advanced cervical cancer, aimed at achieving more precise target

coverage and better critical organ sparing.

#### Study design

Single-center observational study investigating the potential of an MRI-guided adaptive radiotherapy workflow for patients with locally advanced cervical cancer.

#### Study burden and risks

Three extra MRI scans (without contrast agents) will be acquired taking a total of 80 minutes extra time. This procedure is considered to be free of any risks. No extra hospital visits are required. The treating physician will evaluate the clinical treatment plan using the additional MRI scans during treatment; in some cases this may result in treatment plan adaptation which may lead to patient benefit.

## **Contacts**

#### **Public**

Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3584 CX NI

Scientific

Universitair Medisch Centrum Utrecht

Heidelberglaan 100 Utrecht 3584 CX NL

## **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

- \* Clinical indication for chemoradiotherapy with curative intent (one of the following):
- -FIGO [1] stage IA, IB1 or IIA1 cervical cancer with regional lymph node pathology,
- -FIGO stage IA, IB1 or IIA1 cervical cancer with contraindications for surgery
- -FIGO stage IB2, IIA2, IIB, IIIA, IIIB, or IVA cervical cancer
- \* Medical condition that allows chemoradiotherapy with curative intent
- \* Age \* 18 years
- \* Signed informed consent, obtained before the acquisition of the first additional MRI scan
- \* Able to comply with the variable bladder filling protocol (drinking and voiding instructions, this protocol is part of standard clinical care)

#### **Exclusion criteria**

- \* Patients who meet exclusion criteria for MRI at 1.5T following the protocol of the department of Radiology of the UMC Utrecht
- \* Patients who are mentally or otherwise disabled and/or considered legally incapable
- \* History of previous pelvic radiotherapy
- \* Pregnant or breast-feeding patients

# Study design

## **Design**

**Study type:** Observational invasive

Masking: Open (masking not used)

Control: Uncontrolled Primary purpose: Treatment

#### Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 25-05-2016

Enrollment: 20

Type:	Actua

# **Ethics review**

Approved WMO

Date: 12-11-2015

Application type: First submission

Review commission: METC Universitair Medisch Centrum Utrecht (Utrecht)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

No registrations found.

# In other registers

Register ID

CCMO NL54660.041.15

# **Study results**

Results posted: 17-10-2019

First publication

17-10-2019